Corvera J, Corvera G
Universidad Nacional Autónoma de México, Mexico City.
Am J Otol. 1989 Mar;10(2):142-5.
A retrospective computerized analysis of the records of patients with Meniere's disease was made to evaluate the effect of acetazolamide and chlorthalidone on the rate of hearing loss. Three groups were compared as follows: (1) 79 patients treated with chlorthalidone for 5 to 13.4 years; (2) 42 patients medicated with acetazolamide between 5 and 7.8 years; and (3) a control group of 71 patients who received only intermittent symptomatic treatment for vertigo, followed for 5 to 24.1 years. In the short term, after 2 to 6 weeks of treatment, a statistically significant decrease of the average hearing loss was observed with both chlorthalidone and acetazolamide. In the long term, more than 5 years, no preventive effect on the deterioration of the hearing loss could be detected. Both acetazolamide and chlorthalidone can be useful for diagnostic purposes by causing a fluctuation of hearing, as well as for the management of the vertigo attacks, but it is not useful for the long-term prevention of the hearing deterioration in Meniere's disease.
对梅尼埃病患者的记录进行了回顾性计算机分析，以评估乙酰唑胺和氯噻酮对听力损失发生率的影响。比较了三组情况如下：（1）79例接受氯噻酮治疗5至13.4年的患者；（2）42例服用乙酰唑胺5至7.8年的患者；以及（3）71例仅接受眩晕间歇性对症治疗的对照组患者，随访5至24.1年。短期内，治疗2至6周后，氯噻酮和乙酰唑胺均观察到平均听力损失有统计学意义的下降。长期来看，超过5年，未发现对听力损失恶化有预防作用。乙酰唑胺和氯噻酮均可通过引起听力波动用于诊断目的，以及用于眩晕发作的治疗，但对梅尼埃病听力恶化的长期预防无效。
